Anti-PRG2 Rabbit Polyclonal Antibody for WB, IF-P, ELISA - P13727

Core Product Specifications and Parameters

Biological Background: PRG2 Function and Localization

• The PRG2 gene encodes bone marrow proteoglycan, also known as proteoglycan 2, eosinophil major basic protein (MBP) homolog, or proMBP. The protein exists as both an inactive proform and a mature, active secreted form generated through proteolytic processing.
• PRG2 functions as a potent cytotoxin and helminthotoxin, playing a critical role in antiparasitic defense mechanisms. It also induces non-cytolytic histamine release from human basophils, contributing to immune hypersensitivity reactions.
• The proform of PRG2 acts as a proteinase inhibitor, specifically reducing the activity of pregnancy-associated plasma protein-A (PAPPA), and is highly abundant in placenta and pregnancy serum.
• PRG2 is a secreted protein that localizes to cytoplasmic vesicles, particularly secretory vesicles, consistent with its release during eosinophil degranulation and immune responses.
• The protein has been detected in plasma, urine, and placenta, with lower expression in tissues such as kidney, myometrium, endometrium, ovaries, breast, prostate, bone marrow, and colon.
• Post-translational modifications include glycosylation, disulfide bond formation, and nitration, and it contains a heparin-binding domain. These features, along with alternative splicing, contribute to its structural and functional diversity.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 17–222 of human PRG2 (NP_002719.3), covering the mature protein region. This design may recognize both proform and mature PRG2 in Western blot, potentially yielding bands around 23–25 kDa as observed.
• For WB, consider using reducing conditions and validate the detected band sizes against predicted molecular weights of the proform (~25 kDa) and mature form (~23 kDa) in relevant human samples such as eosinophil lysates or placental tissue extracts.
• For IF-P, fixation and permeabilization conditions should be optimized; PRG2 is expected in cytoplasmic secretory vesicles. Strong signal may be obtained in tissues with high eosinophil infiltration or placenta.
• ELISA applications may be used for detecting PRG2 in serum, plasma, or urine, but assay conditions (capture/detection) should be validated for the proform and mature form individually if differentiation is required.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. This anti-PRG2 polyclonal antibody is suited for immunology and infectious disease research, and CamelBio can support your projects with validated antibody pairs, optimized bulk antibodies, and ancillary reagents for assay development. For rare targets or custom requirements, our sourcing team ensures timely delivery of high-quality raw materials.